A simple blood test can show the development of lung cancer two years earlier than conventional tests. It is important result obtained from a study conducted by National Cancer Institute (INT) of Milan. A large step forward in the fight against this serious form of cancer, which each year kills many victims, especially among heavy smokers. The results of this research published in the Journal of Clinical Oncology were recently presented at the conference of the American Association for Cancer Research (Aacr) and the International Association for the Study of Lung Cancer (Ialsc), which is was held in California.

According to the study, even before the diagnosis obtained with the spiral Tac (the method currently used to detect disease earlier), you can find out in advance if you are developing a lung cancer, undergoing an ordinary blood test. This, in particular, thanks to a test based on the analysis of micro RNA circulating, namely those of ribonucleic acid molecules that modulate gene expression and which are expressed in a deviant in tumor forms. According to the research of the Int Milan which saw the collaboration of the University of Parma and the Mario Negri Institute in Milan – this examination also has the ability to reduce significantly the proportion of false positives often obtained with the radiological investigation of reference.


Resorting to early diagnosis based on simple blood test, not only has “the 80 percent reduction of false positives obtained by combining the test results of micro RNA and Tac spiral”, but also says, director of Thoracic surgery either inside “a reduction of costs and risks associated with the repeated radiological investigations or the use of other invasive diagnostic methods to the patient.”

The results of the analysis of micro RNAs have been shown to be independent of the stage of lung cancer and the time interval between the molecular analysis and identification of the tumor using spiral Tac. In essence, “the results of our study – says Gabriella Sozzi, director of the National Institute of Cancer Genetics Unit tumors support the use of molecular testing as a tool to improve the early identification of cancer to the lung. ”

The test developed by researchers at the Int will be launched this year, for the first time, the United States of America by Gensigna, London-based private company that deals with the development of molecular diagnostic tests.